Cargando…
Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome
SIMPLE SUMMARY: Many patients with primary central nervous system lymphoma (PCNSL) participate in clinical trials. The inclusion criteria for these trials are largely uniform among various trials on first-line treatment. Therefore, there is a lack of data on therapeutic management and prognostic fac...
Autores principales: | Seidel, Sabine, Margold, Michelle, Kowalski, Thomas, Baraniskin, Alexander, Schroers, Roland, Korfel, Agnieszka, Thiel, Eckhard, Weller, Michael, Martus, Peter, Schlegel, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230869/ https://www.ncbi.nlm.nih.gov/pubmed/34208229 http://dx.doi.org/10.3390/cancers13122934 |
Ejemplares similares
-
HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis
por: Seidel, Sabine, et al.
Publicado: (2019) -
HDMTX-based polychemotherapy including intraventricular therapy in
elderly patients with primary CNS lymphoma: a single center
series
por: Seidel, Sabine, et al.
Publicado: (2020) -
The value of bone marrow biopsy for staging of patients with primary CNS lymphoma
por: Margold, Michelle, et al.
Publicado: (2021) -
Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis
por: Seidel, Sabine, et al.
Publicado: (2023) -
High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity
por: Seidel, Sabine, et al.
Publicado: (2022)